Supplementary Table S2 from A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600–Mutant Solid Tumors

Characteristics of patients who received prior treatment with BRAF and/or MEK inhibitors (N=10). A table summarizing the characteristics, PTEN status and best response in patients who previously received BRAF and/or MEK inhibitors (N=10).